Sweden

Dela

Välj datumintervall -
Taggar ( valda)

ArcticZymes Technologies Initiates Share Buyback to Support Employee Share Purchase Program

Tromsø, Norway, November 25[th], 2025 – ArcticZymes Technologies ASA (OSE: AZT) has decided to initiate a share buyback program pursuant to the authorization granted by the Annual General Meeting held on 27 May 2025The purpose of the program is to settle share-based incentive programs for employees and management where employees can acquire shares at 15% discount from market price. The buyback will be carried out in accordance with Article 5 of the EU Market Abuse Regulation (MAR) and Commission Delegated Regulation (EU) 2016/1052, which provides a “safe harbour” from market manipulation

ArcticZymes ASA Appoints New Exclusive European Distributor for its Bioprocess Nuclease Range.

Tromsø, Norway, October 29[th], 2025 – ArcticZymes Technologies ASA (OSE: AZT) and Brenntag Specialties Pharma today announced the signing of an exclusive distribution agreement for ArcticZymes’ SAN-HQ and M-SAN enzyme products across Europe. Under this agreement, Brenntag will act as the exclusive distributor for these products, while ArcticZymes will continue to maintain direct relationships with customers in the region.This collaboration marks the most recent implementation of ArcticZymes new channel strategy and will significantly enhance the accessibility of ArcticZymes’ innovative

ArcticZymes Technologies Q4 and full year 2022 results

Tromsø, Norway, 2[th] February 2022 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 28.2 million (40.5) and an EBITDA of NOK 1.3 million (20.8) for the fourth quarter of 2022.Highlights from Q4 and the full year 2022 · ArcticZymes Technologies (AZT) had Q4 sales of NOK 28.2 million a reduction of 30% (Q4 2021: NOK 40.5 million) and sales for the full year of NOK 137.0 million growing by 7% (12M 2021: NOK 128.0 million) · AZT had a positive EBITDA for Q4 of NOK 1.3 million, a reduction of NOK 19.5 million (Q4 2021: NOK 20.8 million) and a positive EBITDA for 2022 of NOK

Biotec Pharmacon ASA - Notice of Annual General Meeting

The annual general meeting ("AGM") in Biotec Pharmacon will be held on Thursday 14. May 2020 at 13.00 CET at SIVA Innovation Centre (Linken), Sykehusvegen 23, Tromsø.Please find the notice including agenda for the meeting and appendices attached to this disclosuere. The notice and appendicies will aslo be made available on the Company's homepage www.biotec.no.Due to the Corona pandemic, a number of measures are being taken to prevent the virus from spreading. The measures are implemented to ensure the health and safety of the Company's employees, shareholders and directors. We also want

Biotec Pharmacon Q1 2020 Report

Tromsø, Norway, 23 April 2020 – Biotec Pharmacon (OSE: Biotec) reported sales of NOK 34.3 million (14.8) and an EBITDA of NOK 13.8 million (-3.9) for the first quarter of 2020. Improvements are in all areas of the business.Highlights from Q1 2020 · New Group strategy kicks off in the right direction on the promise to drive the company into profitability during 2020 · Gross profit for the Group improved 118% to NOK 26.2 million (Q1 2019: NOK 12.0 million) · ArcticZymes had first quarter sales of NOK 18.5 million growing by 135% (Q1 2019: NOK 7.9 million) · Biotec BetaGlucans

Biotec Pharmacon ASA appoints Dr. Jethro Holter as CEO

(Tromsø 22. April 2020) Biotec Pharmacon ASA (OSE: “BIOTEC”) announced today that its Board of Directors has unanimously appointed Dr Jethro Holter as the Company’s permanent Chief Executive Officer. Dr Holter has been the interim CEO for the last 6 monthsJethro joined ArcticZymes as Managing Director in January 2015. He focused on driving a  new strategic direction channelling the subsidiary’s efforts towards growth, through expanding its B2B client base and implementing a customer-driven innovation approach for new product development. Consequently, the subsidiary has experienced strong

Biotec Pharmacon ASA - Annual report 2019

Enclosed is the 2019 Annual report for Biotec Pharmacon ASA. The annual report is also made available on www.biotec.noThe "Profit & Loss" figures in the 2019 Annual report includes figures relating to "Assets held for sale", which was listed as net under "Net profit Assets held for sale" in the Q4 2019 report.   This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. For additional information, please contact:Børge SørvollCFO+47 952 90187borge.sorvoll@biotec.no

Det finns inga träffar som matchar nuvarande filter
Det finns inga fler träffar som matchar nuvarande filter
Tillbaka till sidans topp

Prenumerera